about
Lanthipeptides: chemical synthesis versus in vivo biosynthesis as tools for pharmaceutical productionBioengineering Lantibiotics for Therapeutic SuccessApplying Convergent Immunity to Innovative Vaccines Targeting Staphylococcus aureus.In vivo pharmacokinetics and pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine thigh infection model.Candidacidal Activity of Selected Ceragenins and Human Cathelicidin LL-37 in Experimental Settings Mimicking Infection Sites.Chemical synthesis of the lantibiotic lacticin 481 reveals the importance of lanthionine stereochemistry.Novel avenues for Clostridium difficile infection drug discovery.Developing new antibacterials through natural product research.Natural product and natural product derived drugs in clinical trials.Genome database mining for the discovery of novel lantibiotics.Pharmacological and pharmacokinetic properties of lanthipeptides undergoing clinical studies.Contributions of the σ(W) , σ(M) and σ(X) regulons to the lantibiotic resistome of Bacillus subtilis.Characterization of the stereochemical configuration of lanthionines formed by the lanthipeptide synthetase GeoM.Incorporation of Nonproteinogenic Amino Acids in Class I and II Lantibiotics.Differences in the antibacterial activity of nisin and bovicin HC5 against Salmonella Typhimurium under different temperature and pH conditions.Fighting biofilms with lantibiotics and other groups of bacteriocins.
P2860
Q26748638-76BCF7BE-F771-4F61-8F12-B98F36ABF1AEQ26774123-2F7C9DE5-8E01-426B-BF46-11385FBBD54EQ34250054-2B0AFE5F-265A-4672-9352-2A280303ED21Q35105932-AF4C5695-2CAF-491C-8E79-66DD3FA9543FQ36055572-168C9818-79EE-4D4D-B08A-BF7738A81B51Q37078724-EB5BD183-0CEE-41C7-ACF0-E28EC75360B6Q38083297-8CFE9A76-55E9-4176-996F-9E8BA04C6690Q38088256-498FFFEC-5F24-4705-8801-2C80B1B0FF85Q38247457-853B47CF-C79E-47F9-A6DC-91C24D69C96BQ38901217-13F0A3CA-C293-4FEF-AA46-1E76AADE7896Q39065285-59DDE590-0DBE-49C4-97B7-81A1E4E679D4Q41017751-372E6DA0-5CF7-4E89-B561-852ADA146A61Q42696478-E9B7A800-BAA9-433B-8CD8-C24A302D5675Q50033661-C04FAD93-C801-4BD3-97D4-58324FE140C4Q50424919-4B9880B9-C98D-40D6-9346-6F56230103D3Q55223927-3A263D75-26B1-4CCF-84D7-3253C410A58F
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
New horizons for host defense peptides and lantibiotics
@ast
New horizons for host defense peptides and lantibiotics
@en
New horizons for host defense peptides and lantibiotics
@nl
type
label
New horizons for host defense peptides and lantibiotics
@ast
New horizons for host defense peptides and lantibiotics
@en
New horizons for host defense peptides and lantibiotics
@nl
prefLabel
New horizons for host defense peptides and lantibiotics
@ast
New horizons for host defense peptides and lantibiotics
@en
New horizons for host defense peptides and lantibiotics
@nl
P2860
P3181
P1476
New horizons for host defense peptides and lantibiotics
@en
P2093
Richard W Scott
P2860
P304
P3181
P356
10.1016/J.COPH.2012.06.006
P407
P577
2012-10-01T00:00:00Z